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Abstract 
Alzheimer’s disease is the most prevalent form of dementia in the elderly but the precise causal 
mechanisms are still not fully understood. Growing evidence supports a significant role for Aβ42 
oligomers in the development and progression of Alzheimer’s. For example, intracellular soluble Aβ 
oligomers are thought to contribute to the early synaptic dysfunction associated with Alzheimer’s 
disease, but the molecular mechanisms underlying this effect are still unclear. Here, we identify a 
novel mechanism that contributes to our understanding of the reported synaptic dysfunction. Using 
primary rat hippocampal neurons exposed for a short period of time to Aβ42 oligomers, we show a 
disruption in the activity-dependent phosphorylation cycle of SynapsinI at Ser9. SynapsinI is a pre-
synaptic protein that responds to neuronal activity and regulates the availability of synaptic vesicles 
to participate in neurotransmitter release. Phosphorylation of SynapsinI at Ser9, modulates its 
distribution and interaction with synaptic vesicles. Our results show that in neurons exposed to Aβ42 
oligomers, the levels of phosphorylated Ser9 of SynapsinI remain elevated during the recovery period 
following neuronal activity. We then investigated if this effect could be targeted by a putative 
therapeutic regime using valproic acid (a short branch-chained fatty acid) that has been proposed as 
a treatment for Alzheimer’s disease. Exposure of Aβ42 treated neurons to valproic acid, showed that 
it restores the physiological regulation of SynapsinI after depolarisation. Our data provide a new 
insight on Aβ42-mediated pathology in Alzheimer’s disease and supports the use of Valproic acid as a 
possible pharmaceutical intervention for the treatment of Alzheimer’s disease. 
 
Highlights 
 Activity dependent availability of synaptic vesicles is enhanced by Aβ42 oligomers  
 Aβ42 oligomers reduce the recovery of SnpI after neuronal activity 
 VPA reverses the effects of Aβ42 oligomers on SnpI 
 
Key Words 
Alzheimer’s, Aβ42, Synaptic vesicles, neuronal activation, Synapsin, VPA  
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Introduction  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, characterised by 
synaptic dysfunction and neuronal loss. The phenotypical hallmarks of the disease are intracellular 
neurofibrillary tangles (NFT) consisting of aggregates of hyperphosphorylated tau protein and 
extracellular deposits (amyloid plaques) comprising amyloid-beta (Aβ) peptides. Aβ peptides are 
hydrophobic and readily oligomerise and aggregate, forming fibrillar structures deposited in 
extracellular plaques. It is currently believed that early synaptic dysfunction of excitatory synapses 
underlying memory impairment during the early stages of the disease is induced by soluble oligomeric 
forms of Aβ42 (Aβ42O) and precedes plaque formation (Hsia et al., 1999; Lacor et al., 2007; Lambert 
et al., 1998; Oddo et al., 2003; Oddo et al., 2006; Shankar et al., 2007; Shrestha et al., 2006; Walsh et 
al., 2002; Wang et al., 2002). Exposure of neurons to Aβ42O induces a multitude of synaptic defects 
such as a decrease in excitatory post synaptic potentials (EPSPs) and inhibition of NMDAR-dependent 
LTP. These defects have been associated with increased amounts of glutamate at the synaptic cleft, 
either through the reduction of glutamate uptake, or by enhanced glutamate release. Consequently, 
excitotoxicity, desensitisation of the glutamate receptors and inhibition of LTP is induced (Abramov et 
al., 2009; Arias et al., 1995; Harris et al., 1995; Kabogo et al., 2008; Li et al., 2009; Li et al., 2011; Puzzo 
et al., 2008).  
Recent studies suggest that intracellular Aβ42 (iAβ42) induces presynaptic defects by 
interfering with neurotransmitter (NT) release (Abramov et al., 2009; Billings et al., 2005; Kelly and 
Ferreira, 2007; Oddo et al., 2003; Oddo et al., 2006; Park et al., 2013; Parodi et al., 2010; Ripoli et al., 
2014; Russell et al., 2012). It has been shown that iAβ42 induces depletion of synaptic vesicles (SV) in 
a time and concentration dependent manner (Parodi et al., 2010) and affect the relative size of 
different SV pools (Park et al., 2013). Although several effects of Aβ peptides on SV dynamics have 
been described, how these effects arise is still not fully understood. Recently, we reported that a 
contributing factor to presynaptic defects could be the disruption of the interaction between two SV 
proteins, Synaptophysin (Syp) and Synaptobrevin by Aβ42O (Russell et al., 2012). Here, we provide 
evidence of an additional mechanism by which Aβ42O can modulate the availability of SVs. Our results 
suggest that in neurons exposed to Aβ42O, the phosphorylation dynamics of SynapsinI (SnpI) is 
changed. SnpI belongs to a family of pre-synaptic phosphoproteins that are essential components of 
synaptic fine-tuning and remodelling. They organise the pools of SVs during neuronal activity through 
direct association/dissociation cycles, acting as key regulators of the availability of SVs to participate 
in neurotransmitter (NT) release (Cesca et al., 2010). It has been suggested that Snps serve as adaptor 
proteins that tether SVs to an actin mesh under resting conditions by binding to SVs as well as the 
actin cytoskeleton and clustering them in the resting pool (Cesca et al., 2010; Orenbuch et al., 2012). 
However, activity-dependent phosphorylation/dephosphorylation cycles at key residues of Snps 
induce transient disassembly of Snps from the SVs (Jovanovic et al., 2001). Consequently, SVs are 
released from the resting pool, enabling their participation in neurotransmitter release whilst Snps 
diffuse in the axon (Shupliakov et al., 2011) but readily re-cluster after the cessation of synaptic activity 
(Chi et al., 2001; Hosaka et al., 1999). Ser9  (site1) is within a small N-terminal lipid-binding domain 
that upon synaptic activity, gets phosphorylated, leading to dissociation from SVs (Hosaka et al., 1999). 
Under physiological conditions, activity-dependent increases in pSnpISer9 levels enhance 
neurotransmitter release (Benfenati et al., 1989; Benfenati et al., 1992; Benfenati et al., 1991). 
Interestingly, the levels of phosphorylated SnpI at position 1 (Ser9) are enhanced in AD post-mortem 
tissues (Parks et al., 1991).   
Here we explore the hypothesis that exposure of neurons to Aβ42O has a direct impact on the 
levels of SnpI phosphorylation. Double immunolabeling in primary rat hippocampal neurons was 
performed for SnpI or pSnpISer9 and Synaptophysin (Syp), a synaptic vesicle associated protein that 
labels pre-synaptic boutons. Quantification of the extent of overlap between Syp and SnpI or pSnpSer9, 
showed that although Aβ42O do not interfere with the dispersion pattern of SnpI during neuronal 
activity, they deregulate the phosphorylation/dephosphorylation cycle of pSnpSer9. In addition, we 
examined available drugs that could reverse this effect. Valproic Acid (VPA), a short branched chain 
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fatty acid, is a commonly used drug for treatment of epilepsy and bipolar disorder and based on 
evidence from mouse models, has also been proposed to be beneficial at early stages of AD (Park et 
al., 2014; Qing et al., 2008). VPA has been found to affect LTP and LTD and combat various aspects of 
AD-related pathology (Chang et al., 2010; Hu et al., 2011; Leng et al., 2008; Qing et al., 2008; Williams 
and Bate, 2016; Zhang et al., 2003).  Since VPA has also been shown to prevent Aβ42 induced reduction 
in SV recycling (Williams and Bate, 2016) and to induce clustering of SnpI in developing neurons (Hall 
et al., 2002), we examined if it could be used to reduce the effects of Aβ42O  in the regulation of SnpI.  
Our results show that indeed, VPA can abrogate the effects of Aβ42O on the dynamics of SnpI 
regulation in a concentration dependent manner. 
 
Materials and Methods 
Primary hippocampal neuronal cultures. 
All animal experiments were performed according to Home Office regulations in compliance with the 
Animals Scientific Act 1986. Primary cultures of CA3-CA1 hippocampal neurons were prepared from 
E18 Sprague Dawley rat embryos as previously described (Russell et al., 2012))￼. Briefly, cells were 
plated at a density of either 75,000 or 500,000 cells on poly-D-lysine (Sigma, 0.1mg/ml in borate buffer 
pH 8.5) coated glass cover slips or 6-well plates respectively. The plating medium was DMEM 
supplemented with 5% FBS, penicillin/streptomycin (P/S) and 0.5mM l-glutamine (all from Invitrogen). 
On the next day the medium was changed to full Neurobasal medium (Neurobasal medium 
supplemented with B27, P/S, 0.5mM l-glutamine, all from Invitrogen). Cultures were incubated at 37oC 
and 5% CO2, and were used routinely between 18 to 21 DIV. Immuno labelling for vGlut (Synaptic 
Systems) and Gad65 (Chemicon) was performed to ensure our cultures were enriched in glutamatergic 
neurons (Sup Fig 1) 
Preparation of AβO and neuronal treatment 
Preparation of Aβ peptides and treatment of neurons to study the effects of iAβ42 has been 
previously described (Russell et al., 2012). Briefly, Aβ42 (American peptides) was prepared by 
dissolving the peptide in DMSO (1mM). The reconstituted peptides were diluted in PBS at a working 
concentration of 300μM and stored in aliquots at -80°C. Peptides were diluted in working 
concentration in full Neurobasal medium immediately after thawing and were not frozen again. Since 
reconstituted Aβ42 peptides rapidly aggregate to form oligomers, protofibrils and fibrils, we routinely 
examined the aggregation state of our peptides on native and SDS polyacrylamide gels. On native gels, 
we observed a predominant band with a molecular weight of ~20 kDa (Sup Fig 2A) indicating that our 
peptide preparation consists of small oligomers believed to be the toxic species (Selkoe, 2012). These 
oligomers could be broken down to monomers (4.5 kD) - trimers (13.5 kD) on an SDS PAGE gel (Sup 
Fig 2B) suggesting that they had not adopted a β-sheet conformation. 
To ensure the observed effects were produced by intracellular Aβ42, neurons were treated 
exactly as previously described (Russell et al., 2012). Briefly, neurons were incubated with Aβ42O 
(diluted in full Neurobasal medium at 300nM final concentration) for 30min.  Aβ42O were removed 
by replacing the medium with fresh full Neurobasal medium with or without drugs (for consistency 
medium in control neurons was also replaced) and the cells were left to recover for 2hrs. 
Immunolabelling of primary neurons for Aβ42 (6E10 Ab from Covance) and GluN2A/B ((Chemicon) 
confirmed our previous data and showed Aβ42Os present at the presynaptic compartment of 
glutamatergic synapses (Sup Fig 3). Synchronisation of neurons was performed after the 2hr recovery 
period by replacing the medium with a salt solution containing KCl (70mM KCl, 44mM NaCl, 2mM 
CaCl2, MgCl2, 20mM HEPES and 30mM glucose) for 5min. Recovery of neurons from neuronal activity 
involved washing the cells and incubation for a further 15mins at 37oC and 5% CO2 in fresh full 
Neurobasal medium. 
 
Immunocytochemistry 
 Following treatment, coverslips were rinsed once with pre-warmed (370C) PBS and fixed with 4% 
paraformaldehyde (PFA), 2% Sucrose in PBS. Fixed neurons were washed with TBS, permeabilised with 
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0.1% Tween-20 and 5% horse serum in TBS for 45min at room temperature, and incubated with 
primary antibodies overnight at 4°C. Coverslips were incubated with different combinations of primary 
and secondary antibodies and then mounted using the ProLong Gold reagent (InvitrogenUK). The 
primary antibodies used were combinations of: a rabbit anti-Syp antibody (Santa Cruz, sc-7568) and a 
mouse anti-Snp antibody (Santa Cruz, sc-37662); or a mouse anti-Syp (Sigma UK, S5768) and a Rabbit 
anti- pSnpSer9 antibody (Abcam, ab76260). Fluorescent secondary antibodies were all from Invitrogen: 
anti-rabbit Alexa Fluor 568; anti-mouse Alexa Fluor 488; anti-mouse Alexa Fluor 647. The cells were 
visualised on a spin disc confocal system (CARV from Digital Imaging Solutions) with an EM-CCD 
camera (Rolera/QI Cam 3500) mounted on an Olympus X71 microscope, using a 100x fluoplan 
objective (NA 4.2). The microscope confocal system was supported by Image Pro 6.0 software.  
 
Image analysis 
The image analysis was performed as previously described (Semerdjieva et al., 2013). Briefly, 10-15 
images (from a minimum of three independent experiments) were analysed using the JaCoP plugin 
for ImageJ (Bolte and Cordelieres, 2006), to calculate the split Mander’s coefficient. For consistency, 
the background of each image was removed by selecting two random areas devoid of staining within 
the images, the intensity was measured on each channel independently using ImageJ and the average 
background measurement was removed from the entire single channel image before analysis. No 
threshold was applied to avoid introducing a non-consistent bias to our calculations. To avoid potential 
digital overlap, all images were single section confocal images. 
 
Western blotting 
Proteins were extracted in 20mM HEPES pH7.5, 1mM EDTA, 150mM NaCl, 1% NP-40 and 1mM 
dithiothreitol supplemented with protease (Roche) and phosphatase (Thermo Scientific) inhibitor 
cocktails. The protein concentration of the protein extract was determined by Bradford’s Protein 
Assay. 15μg of total protein were separated on 12% Tris-Glycine gels at 120V and transferred to 
nitrocellulose membrane at 10V for 16 hours in transfer buffer (200mM Glycine, 25mM Tris Base, 20% 
Methanol). Blots were blocked with 2.5% non-fat dry milk in Tris-buffered saline (50mM Tris Base, 
150mM NaCl) containing 0.05% Tween-20, pH 7.5, for 1hr and 30mins with agitation. Following this, 
blots were incubated at room temperature for 2 hours with primary antibodies and for 1 hour with 
secondary antibodies diluted in 2.5% non-fat dry milk. Detection of proteins was performed using the 
Odyssey® imaging scanner (LI-COR Biosciences). Primary antibodies used were a mouse anti-Syp IgM 
antibody (Novus Biologicals, NBP1-97459); a mouse anti-Snp antibody (Santa Cruz, sc-37662); a rabbit 
anti-Snp pSer9 antibody (Novus Biologicals, NB300-180), a mouse anti-actin antibody (SIGMA A5316), 
a mouse anti-Aβ (clone 6E10) and a Rabbit p-PP2A(Tyr 307)-Calpha/beta (Santa Cruz, sc-12615-R). 
Fluorescent secondary antibodies used were a goat anti-mouse 680 (NEB, 5470S) and a goat anti-
rabbit 800 (NEB, 5151S).  
 
Statistical analysis 
All data in this study are reported as mean ± SEM. Statistical analysis of data was performed by a one-
way ANOVA followed by a Tukey's multiple comparisons test using the XLSTAT add-in for Excel, or by 
a student’s T-Test. Overall p-values are presented in tables in the supplementary data.  Only significant 
p-values are discussed in the manuscript.  
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Results 
Effect of Aβ42O on the activity-dependent dispersal of SnpI  
We have previously reported that a brief exposure of neurons to nanomolar concentrations 
of Aβ42O followed by a recovery period results in its internalisation and its presence at the presynaptic 
compartment, where it disrupts the interaction between Syp and VAMP2 (Russell et al., 2012). To 
investigate the effects of internalised Aβ42O on the regulation of SnpI we adopted a similar approach. 
Mature hippocampal neurons were cultured for 18-21 days in vitro to provide well-established 
synaptic junctions. Double immunolabeling for SnpI and Syp was performed in fixed neurons to 
visualise how the distribution of SnpI at synapses was altered during neuronal activity following Aβ42O 
treatment in relation to Syp, a synaptic vesicle marker. Initially, we compared the co-localisation of 
SnpI and Syp in non-synchronised cultures between control neurons and neurons exposed to Aβ42O 
for 30 min followed by a 2hr recovery in culture medium. In these experiments, SnpI and Syp showed 
extensive co-localisation in pre-synaptic boutons in the absence or presence of Aβ42O (Fig 1A and D 
respectively). To quantify the dynamic of this distribution, we calculated the extent of overlap 
between SnpI over Syp (expressed by the Mander’s co-efficient value) as previously described 
(Semerdjieva et al., 2013). Our results showed that SnpI overlapped extensively with Syp in both 
untreated and Aβ42O-treated neurons. No difference was found between control and Aβ42O treated 
neurons (Fig 1G, black bars), suggesting that Aβ42O did not affect the diffusion of SnpI from synaptic 
contacts under resting conditions.  
Since neurons in culture fire asynchronously, we hypothesised that an effect of Aβ42O in the 
activity-dependent dispersal of SnpI might be difficult to observe under basal conditions. Thus, we 
repeated our experiment in synchronised cultures. Depolarisation of neurons by exposure to KCl for 
5min prior to fixation induced a reduction in the localisation of SnpI at Syp-labelled synaptic contacts 
(Fig 1B and grey bar in G, with p<0.0001 compared to non-depolarised control neurons) indicating that 
neuronal activity resulted in dispersion of SnpI from pre-synaptic boutons. A similar change in the 
distribution of SnpI was also observed in neurons exposed to Aβ42O following depolarisation (Fig 1E 
and grey bar in G, with p<0.0001 compared to non-depolarised Aβ42O treated neurons).  
Finally, double immunolabeling for SnpI and Syp in neurons allowed to recover for 15 min 
after depolarisation, showed that the co-localisation between the two proteins in both untreated and 
Aβ42O treated neurons was re-established (Fig 1C, F and white bars in G with p<0.0001 compared to 
depolarised neurons). These results confirm previously published data regarding the dynamics of the 
activity-dependent dispersal and re-clustering of SnpI (Chi et al., 2001). In addition, these observations 
indicate that acute exposure of primary neurons to Aβ42O has no effect on the dispersal of SnpI. 
 
Effect of Aβ42 oligomers on activity-dependent phosphorylation of SnpI 
Since our data suggest that Aβ42O do not affect the activity-dependent distribution of SnpI, 
we then investigated if Aβ42O had an effect on its regulation by focusing on the phosphorylation of 
Ser9. To do so, we examined its distribution by double immunolabeling for pSnpISer9 and Syp in neurons 
treated under the same experimental conditions described earlier. In non-synchronised neurons, co-
localization of pSnpSer9 with Syp at pre-synaptic contacts was similar between control and Aβ42O 
treated neurons (Fig 2A, D and black bars in G), although this was not as pronounced as SnpI/Syp co-
localisation. This suggests that under basal conditions, only a fraction of synapses were activated and 
that exposure of neurons to Aβ42O had no detectable effect in the presence of pSnpISer9 at synaptic 
contacts. 
Next, we examined the effect of Aβ42O on the distribution of pSnpSer9 at synaptic contacts of 
synchronised neurons. Double immunolabeling for pSnpISer9 and Syp, showed an overall increase of 
pSnpISer9 at synaptic boutons, compared to asynchronously firing synapses, both in the presence or 
absence of Aβ42O (Fig 2B, E and grey bars in G, with p<0.0001 compared to non-synchronised 
neurons) suggesting that depolarisation of neurons increases the presence of pSnpISer9 at synaptic 
contacts and that Aβ42O treatment does not affect this increase. 
Finally, in neurons recovered for 15 min post-synchronisation, we observed a significant 
reduction of pSnpISer9 labelling at synaptic contacts in control neurons, whereas labelling of pSnpISer9in 
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Aβ42O treated neurons remained pronounced (Fig 2 C, F). Quantification of the extent of overlap 
between Syp and pSnpISer9 in those conditions showed that even though the expected reduction of 
pSnpISer9 at synaptic boutons was observed in control neurons as well as in Aβ42O-treated neurons 15 
min after depolarisation (p<0.0001 for control neurons and p=0.048 for neurons exposed to Aβ42O), 
a significant difference in the presence of pSnpISer9 between control and Aβ42O treated neurons was 
evident (Fig 2G white bars, with p<0.0001 between control neurons and Aβ42O treated neurons). 
Collectively, our data show that in neurons exposed to Aβ42O, the diffusion of SnpI upon 
depolarisation and its subsequent re-clustering at synaptic contacts recovering from neuronal activity 
is not affected. Interestingly however, although the levels of pSnpISer9 at synaptic contacts in control 
and in Aβ42O treated neurons remain similar during the activation period, during the recovery period 
the levels of pSnpISer9 at synaptic contacts remain high in Aβ42O exposed neurons. This suggests that 
even though Snpl re-clusters following neuronal activity in neurons exposed to Aβ42O, its ability to 
interact with SVs is abrogated during that period. 
 
Effects of VPA on the dynamics of SnpI regulation in neuronal cultures 
Our results so far suggest that Aβ42O affect the activity-dependent dynamics of the 
phosphorylation/dephosphorylation cycle of SnpI at Ser9. Since SnpI has an essential role in 
modulating SV dynamics and is likely to have an impact on neurotransmitter release, we next 
investigated if this effect could be reversed by potential therapeutic drugs.  
VPA has been previously reported to affect SnpI clustering in neurons (Hall et al., 2002) , hence 
we examined the effect of VPA on SnpI distribution under our experimental conditions. In these 
experiments, neurons were acutely treated with 10mM VPA for 2 hours after the removal of Aβ42O 
from the medium.  
First, we investigated the effect of VPA alone on SnpI distribution. In non-synchronised 
neurons, double immunolabeling for SnpI and Syp in control and VPA-treated neurons revealed no 
alteration in the dispersal of SnpI in synaptic boutons (Fig 3A, D and black bars in G). In synchronised 
neurons, equivalent VPA treatment caused a small but statistically significant increase of SnpI at 
synapses (Fig 3B, E and grey bars in G, with p=0.03 between control neurons and VPA treated 
neurons,), suggesting that VPA restricts the activity-dependent dispersal of SnpI. Finally, we examined 
the effect of VPA on the re-clustering of SnpI in neurons recovered for 15 minutes after 
synchronisation. Our data showed that VPA treatment had no effect on SnpI re-clustering following 
recovery from neuronal activity (Fig 3 C, F and white bars in G). These results confirm an earlier study 
(Hall et al., 2002) and in addition, show that VPA restricts the activity-dependent dispersal of SnpI in 
mature primary neurons.  
Next we examined the effect of VPA on pSnpISer9. In non-synchronised neurons, double 
immunolabeling for Syp and pSnpISer9 showed slightly elevated levels of pSnpISer9 at synaptic contacts 
in VPA-treated neurons compared to control neurons (Fig 4 A, D and black bars in G, with p=0.026 
between control neurons and VPA treated neurons) indicating that acute treatment of primary 
neurons with VPA marginally restricts the activity-dependent dispersal of pSnpISer9. In synchronised 
neurons, VPA treatment did not alter pSnpISer9 distribution (Fig 4 B, E), as confirmed by 
quantification of pSnpISer9 to Syp overlap (Fig 4 G, grey bars). Similarly, VPA treatment did not alter 
the distribution of pSnpISer9 at synaptic contacts of neurons recovered for 15 min after depolarisation 
as confirmed by our calculations (Fig 4 C, F and white bars in G). These results suggest that VPA has a 
limited effect on the distribution of pSnpISer9. 
 
VPA reverses the effects of Aβ42 oligomers on pSnpISer9 
 We next examined if co-treatment of neurons with VPA affects the Aβ42O induced increase of 
pSnpISer9 at the presynapse. To ensure that the internalisation of Aβ42O was not affected, we 
incubated neurons with VPA after removal of Aβ42O containing culture medium. In these experiments 
the localisation of pSnpISer9 at synaptic contacts was assessed in control and in Aβ42O treated neurons 
as previously described and was compared to neurons exposed to Aβ42O for 30 min followed by 
incubation with medium containing VPA. We initially carried this out in neurons recovering from 
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neuronal activity. Double immunolabeling for pSnpISer9 and Syp showed a reduction of pSnpISer9 at the 
presynapse in recovering Aβ42O/VPA treated neurons compared to Aβ42O treated neurons 
recovering in medium without VPA (Fig 5 A-C). Quantification of the extent of overlap between Syp 
and pSnpISer9 confirmed our observation (Fig 5 D, p<0.0001 compared to Aβ42O treated neurons). 
These results suggest that VPA inhibits Aβ42O from inducing elevated levels of pSnpISer9 at synaptic 
contacts in mature primary rodent neurons.  
 Finally, to show that co-treatment of neurons with Aβ42O and VPA had no additive effect, we 
examined if the combined exposure of Aβ42O and VPA in non-synchronised and synchronised neurons 
affected the distribution of pSnpISer9 (Sup Fig 4 and 5 respectively). Our results showed that pSnpISer9 
levels were similar in all three conditions. Furthermore, the marginal increase of pSnpISer9 levels at 
synaptic contacts in non-synchronised neurons treated with VPA was abolished in neurons pre-treated 
with Aβ42O (Sup Fig 4 D). This data suggests a possible antagonistic effect between Aβ42O and VPA.  
 
Aβ42 oligomers affect the phosphorylation cycle of SnpI  
Our results so far showed that exposure of neurons to Aβ42O results in sustained levels of 
pSnpISer9 at the pre-synaptic compartment of neurons recovering from depolarisation and that VPA 
attenuates this effect. We next examined if the increased levels of pSnpISer9 at synaptic contacts was 
due to restricted dispersal of pSnpISer9 or due to deregulation of the phosphorylation cycle of SnpI at 
Ser9. To do so, we examined the overall protein levels of both SnpI and pSnpISer9 for each condition by 
western blotting using protein extracts from neurons treated as previously described. We focused our 
analysis on protein extracts that were obtained from synchronised neurons and from neurons that 
recovered for 15 min after depolarisation (Fig 6).  
First, we examined if treatment of neurons with either Aβ42O, VPA, or their combination 
(Aβ42O/VPA) affected the total amount of SnpI in depolarised hippocampal neurons. Western blots 
using antibodies for SnpI and actin (Act) were performed and the ratio of the signal intensity of SnpI 
over Act was calculated for all conditions and normalised against the SnpI/Act ratio of synchronised 
control neurons (marked as 100%). In addition, we also included co-treatment of Aβ42O with lower 
concentrations of VPA (1mM). Our results showed that in depolarised neurons (Fig 6 B black bars) and 
neurons allowed to recover for 15min (Fig 6B white bars), treatment with Aβ42O, VPA or both did not 
significantly alter the levels of SnpI.  
Next, we examined the relative levels of pSnpISer9 under the same conditions (Fig 6C, D). 
Western blotting of protein extracts with antibodies for pSnpISer9 and SnpI was performed and the 
ratio of the signal intensity of pSnpISer9 over SnpI was calculated for all conditions. The pSnpISer9/SnpI 
ratios were normalised to the ratio calculated from depolarised control neurons (marked as 100%). 
Comparison of the levels of pSnpISer9 after synchronisation for all treatments did not reveal any 
difference compared to control neurons (Fig 6D, black bars), suggesting that activity-dependent 
phosphorylation of SnpI at Ser9 remains unaffected by Aβ42O, VPA, or their combination. These 
results also suggest that the increase of pSnpISer9 at the presynaptic compartment in VPA treated 
neurons is not due to an increase in phosphorylation levels, but due to an increase in clustering of 
pSnpISer9. However, differences were observed in neurons allowed to recover for 15 minutes after 
synchronisation (Fig 6D, white bars). Initially, we confirmed that the levels of pSnpISer9 were 
significantly reduced in recovering control neurons since this residue is believed to be 
dephosphorylated following neuronal activity (Fig 6D, p<0.0001 compared to control synchronised 
neurons). Although there was a reduction in the levels of pSnpISer9 in all conditions for recovering 
neurons relative to synchronised neurons (Fig 6D, p<0.05), there were significantly higher levels of 
pSnpISer9 in Aβ42O treated neurons compared to control neurons (Fig 6D, p=0.015). Interestingly, 
incubation with VPA restored the physiological cycle of SnpI dephosphorylation at Ser9 in a 
concentration-dependent manner (p=0.045 at 1mMVPA and p=0.005 at 10mM VPA compared to 
Aβ42O treated neurons).  
These results confirm our previous observation and suggest that the elevated levels of 
pSnpISer9 at the presynapse of neurons exposed to Aβ42O is due to sustained levels of phosphorylated 
SnpI at position Ser9 rather than an increase in clustering of SnpI.  Moreover, our data indicate that 
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the sustained levels of pSnpISer9 after depolarisation could be attenuated by a brief exposure of 
neurons (2hrs) to a near therapeutic dose of VPA (1mM), although a higher dose of 10mM was more 
effective.  
Finally, to confirm that the deregulation of pSnpISer9 phosphorylation dynamics was specifically 
induced by Aβ42O, we repeated our experiments using an inverted Aβ peptide. Neurons were exposed 
to Aβ42O or to the inverted peptide and protein extracts from synchronised and recovered neurons 
were subjected to western blot analysis for SnpI and pSnpISer9 levels as previously described (Sup Fig 
6). Our results showed that the elevated levels of pSnpISer9 in recovered neurons were only detectable 
in neurons exposed to Aβ42 and not in control neurons or in neurons exposed to the inverted Aβ 
peptide. 
 
Aβ42 oligomers induce sustained phosphorylation of pSnpISer9 
Serine 9 in domain A of SnpI is phosphorylated by PKA and CaMKI/IV. Under basal conditions, 
low levels of constitutive phosphorylation are detected that rapidly increase following a 
depolarisation-induced Ca2+ influx (Czernik et al., 1987; Hosaka et al., 1999). The phosphate group on 
serine 9 is then removed by the phosphatase PP2A (Jovanovic et al., 2001). PP2A is a major 
serine/threonine phosphatase. It is a trimeric complex consisting of a core complex of a 65 kDa 
scaffolding subunit (A) and a 36 kDa catalytic subunit (C). The specificity and activity of PP2A is 
conferred when the core complex interacts with the B regulatory subunit. Phosphorylation of Tyr307 in 
the conserved C-terminus of the catalytic subunit inactivates PP2A (Chen et al., 1992). To examine 
sustained levels of pSnpISer9 in neurons exposed to Aβ42O were due to increased phosphorylation or 
decreased dephosphorylation activity on Ser9, we examined the relative phosphorylation levels of the 
catalytic subunits of PP2AC in extracts from neurons treated as previously described. Western blots 
using antibodies for Tyr307-pPP2AC α/β and actin (Act) were performed and the ratio of the intensity of 
Tyr307-pPP2AC over Act was calculated for all conditions and subsequently normalised against the ratio 
of synchronised control neurons (marked as 100%). Our results showed that the phosphorylation 
levels of Tyr307-pPP2AC were consistent in all conditions (Fig. 7). These results show that Aβ42O do not 
inactivate PP2A suggesting that the sustained levels of pSnpISer9 are due to sustained phosphorylation 
of Ser9.  
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Discussion  
Aβ42O disrupt the regulation of SnpI 
Extensive research has shown that synaptic dysfunction precedes the cognitive impairment in 
AD (Selkoe, 2002). However, the initial events underlying the early phases of this dysfunction are still 
not fully understood. Although there are several reports showing that intraneuronal accumulation of 
Aβ42 has a key role in early synaptic dysfunction (Gouras et al., 2010; Gouras et al., 2000; LaFerla et 
al., 2007; Oddo et al., 2006), the mechanisms are still obscure. Increasing evidence suggests that the 
aetiology of synaptic dysfunction in AD, might be linked to defects in the presynaptic bouton (Abramov 
et al., 2009; Parodi et al., 2010; Puzzo et al., 2008; Russell et al., 2012). Even though the cellular and 
molecular mechanisms are still poorly understood, these presynaptic defects have been associated 
with aberrant glutamate release promoting the activation of extrasynaptic neurotransmitter 
receptors, inducing the well-established excitotoxicity (Bordji et al., 2010; Li et al., 2011; Talantova et 
al., 2013), the inhibition of NMDAR-dependent LTP and a decrease in EPSPs (Walsh et al., 2002; Wang 
et al., 2002), the cellular and molecular mechanisms are still poorly understood. 
To explore the mechanisms of neurotransmitter release affected by Aβ42O, we investigated 
if SnpI could be a target of Aβ42O. It has been shown in homogenates of post-mortem brains from 
individuals with confirmed AD, that SnpI was less susceptible to cAMP dependent phosphorylation in 
vitro on Ser9 due to higher basal phosphorylation levels in the diseased tissue (Parks et al., 1991). 
Considering this, we hypothesised that the dispersion of SnpI or its binding to SVs might be affected 
by Aβ42O. Comparing the extent of overlap between SnpI and Syp in neuronal cultures that were 
either non-synchronised, synchronised or were left to recover for 15min after synchronisation, we 
confirmed previous findings and showed in control neurons that activity dependent dispersion of SnpI 
from synaptic contacts was restored after 15min of recovery (Chi et al., 2001). We found no evidence 
that Aβ42O had a significant impact in this dispersion. Next, we examined if Aβ42O could affect the 
phosphorylation dynamics of SnpISer9 that has been associated with binding to SVs. We confirmed 
previous findings and showed a transient increase of pSnpISer9 at synaptic contacts of control 
depolarised neurons that was quickly restored in recovered neurons. Interestingly, in Aβ42O treated 
neurons recovering from depolarisation the presence of pSnpISer9 at synaptic contacts was more 
pronounced compared to control. These results suggest that Aβ42O could alter the function of SnpI, 
either by preventing or delaying the dephosphorylation of SnpISer9 after depolarisation, or by 
promoting clustering of pSnpISer9 at synaptic contacts during the recovery period. 
Having established the effects of Aβ42O in the regulation of SnpI, we then looked for available 
drugs that could antagonise this effect and identified VPA as a candidate molecule. VPA has been 
shown to induce clustering of SnpI (Hall et al., 2002) and also to prevent Aβ42O induced reduction in 
SV recycling (Williams and Bate, 2016). We confirmed previous reports suggesting that VPA can induce 
SnpI clustering (Hall et al., 2002) and showed that in mature neurons exposed to VPA the activity-
dependent dispersion of SnpI from the synaptic bouton was reduced. Furthermore, VPA induced a 
minor increase of pSnpISer9 at synaptic contacts in non-synchronised neurons, confirming a role of VPA 
in the activity dependent clustering of SnpI. In the presence of Aβ42O though, the minor presynaptic 
increase of pSnpISer9 localisation induced by VPA was averted. Similarly, VPA inhibited Aβ42 from 
maintaining elevated levels of pSnpISer9 at synaptic contacts after the recovery period, suggesting that 
VPA and Aβ42 oligomers might act antagonistically on the regulation of SnpI.  
To demonstrate if the pre-synaptic increase of pSnpISer9 was due to deregulation of the 
phosphorylation cycle of SnpI rather than clustering of pSnpISer9, the relative protein levels of SnpI and 
pSnpISer9 were analysed. Since the amount of pSnpISer9 was increased in neurons exposed to Aβ42O 
and recovering from depolarisation, we concluded that the increased labelling of pSnpISer9 at the 
presynapse was a result of an imbalance between dephosphorylation and/or sustained kinase activity 
on SnpI at Ser9 rather than a defect in clustering. Finally, since there weren’t any differences in the 
phosphorylation levels of Tyr307 of the catalytic domain of PP2A we concluded that Aβ42O induced 
sustained kinase activity in depolarised hippocampal neurons.   
 
Intracellular Aβ42: acute and chronic effects 
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It is important to understand how the data from our experiments relate to the synaptic 
dysfunction in early AD patients and to offer an explanation of available data regarding the effects of 
Aβ42 in NT release and SV availability (Abramov et al., 2009; Billings et al., 2005; Kelly and Ferreira, 
2007; Oddo et al., 2003; Park et al., 2013; Parodi et al., 2010; Puzzo et al., 2008; Ripoli et al., 2013; 
Russell et al., 2012). Our data suggest that in neurons exposed to Aβ42O, the sustained 
phosphorylation levels of SnpISer9 after neuronal activity would prevent SnpI from stabilising SVs to the 
reserve pool after depolarisation, promoting an increase in their availability and consequently in 
glutamate release. This hypothesis would support several reports showing that Aβ42O affect 
glutamate release in a concentration and time dependent manner (Abramov et al., 2009; Parodi et al., 
2010; Puzzo et al., 2008; Russell et al., 2012) and can be used to propose a mechanism to explain how 
the organisation of the SV pools is affected. For instance, Parodi et al. showed that exposure of 
neurons to low concentrations of Aβ provides a time dependent bell shaped effect in neurotransmitter 
release, with a significant increase during the first two hours of exposure followed by a substantial 
decrease below control levels after 24 hrs of exposure. What is more, the increased probability of 
release was associated with an increase of intracellular Ca2+ levels (Parodi et al., 2010). Our data fit 
well with this model since sustained intracellular Ca2+ levels would sustain CamKI/IV activity that 
would, in turn, maintain the increased levels of SnpISer9 we observed. Consequently, since increased 
SnpISer9 levels have been linked to an increased probability of NT release (Fiumara et al., 2004), the 
deregulation of the phosphorylation dynamics of SnpI can be a contributing factor to the aberrant 
glutamate release induced by Aβ42O during the initial exposure time. Furthermore, we have 
previously shown that Aβ42O disrupt the interaction between Syp and VAMP2 (Russell et al., 2012) at 
the presynapse. Syp regulates trafficking of VAMP2-containing SVs to the presynaptic bouton and 
upon stimulation the two proteins dissociate allowing VAMP2 to partake in the formation of the 
SNARE complex (Pennuto et al., 2003). Thus, the disruption of the Syp/VAMP2 complex by Aβ42O, 
would permit VAMP2 to participate in the formation of stable SNARE complexes. The increased 
probability of SNARE complex formation combined with an increased availability of SVs due to 
sustained pSnpISer9 levels could well be an additional contributing factor to the reported increase in 
the probability of glutamate release (Abramov et al., 2009; Parodi et al., 2010; Puzzo et al., 2008; 
Russell et al., 2012). In addition, it is likely that the disruption of the Syp/VAMP2 complex and the 
deregulation of SnpI would have a substantial additive impact in prolonged exposure to Aβ42O. 
Sustained phosphorylation levels of SnpI at Ser9, would prevent binding of SVs to the presynaptic actin 
cytoskeleton, allowing them to diffuse along the axon (Orenbuch et al., 2012). Inhibition of the 
Syp/VAMP2 complex formation by Aβ42O, would impede redistribution of the diffused SVs to the 
presynaptic terminal. This would contribute to the reported reduction of the size and regeneration of 
the SV pools (Bonanomi et al., 2007; Park et al., 2013; Parodi et al., 2010; Pennuto et al., 2003).  
We also found evidence of a novel mode of action of VPA. VPA acts antagonistically to Aβ42O 
and prevents the deregulation of the phosphorylation dynamics of SnpI. Since this de-regulation is 
possibly an early event in the synaptic dysfunction induced by Aβ42O, we could hypothesise that early 
treatment with VPA would be more effective in antagonising these effects. Indeed, it has been shown 
that early application of the drug in a mouse model of AD was important to improve memory deficits 
(Qing et al., 2008). Whether VPA would be a suitable molecule to treat AD patients at later stages, 
depends on whether VPA interferes with molecular mechanisms associated with the later stages of 
AD which are yet to be characterised. 
In conclusion, we believe that this study reveals a novel target of Aβ42 oligomers at the 
synapse, and highlights a mechanism that contributes to defective SV dynamics, which could 
contribute to the early synaptic dysfunction in AD. Importantly, we also provide an insight into a 
therapeutic role of VPA in protecting against Aβ42O -mediated synaptic deficits in AD. Collectively, 
these findings suggests a role for intraneuronal Aβ42O at the presynapse that could be a significant 
contributor to the onset and development of the disease. We believe this to be noteworthy since 
researching the effects of Aβ42 at the presynapse could help explain the progression of the disease, 
but will also enable identification of additional targets, essential for the development of efficient AD 
therapies. 
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Figure legends  
Figure 1 
Representative images of double immunolabeling for Syp (green) and SnpI (red) in control (A-C) and 
Aβ42O (300nM) treated primary hippocampal neurons (D-F) that were either non-synchronised (A, D), 
synchronised (B, E) or assayed 15min post synchronisation (C, F). High magnification of the boxed area 
is presented at the bottom of each picture. The extent of overlap between SnpI and Syp represented 
by the Mander’s coefficient (G) showed an extensive overlap between the two proteins in non-
synchronised neurons, that was temporarily reduced upon synchronisation and re-established after 
15min of recovery in both, control and Aβ42O treated neurons (M=0.74±0.07, 0.34±0.06 and 
0.63±0.16 in control and 0.73±0.09, 0.40±0.12 and 0.74±0.05 in Aβ42O treated neurons respectively). 
n=3 independent experiments. ***: p<0.0001. Scale bar, 10μm.  
Figure 2 
Representative images of double immunolabeling for Syp (green) and pSnpISer9 (red), in control (A-C) 
and Aβ42O (300nM) treated primary hippocampal neurons (D-F) that were either non-synchronised 
(A, D), synchronised (B, E) or assayed 15min post synchronisation (C, F). High magnification of the 
boxed area is presented at the bottom of each picture. The extent of overlap between Syp and 
pSnpISer9 represented by the Mander’s coefficient (G) showed low levels of overlap between the two 
proteins in non-synchronised control and Aβ42O treated neurons, that was significantly increased 
upon synchronisation with M=0.19±0.07, 0.45±0.15 (p<0.0001, n=3) for control and 0.16±0.07, 
0.52±0.19 (p<0.0001, n=3) for Aβ42O-treated neurons respectively. 15min post synchronisation, 
pSnpISer9 in control neurons was barely detectable (C) whereas in Aβ42O treated neurons a clear 
signal was evident (F). The extent of overlap between Syp and pSnpISer9was severely reduced in control 
neurons compared to synchronised (M=0.06±0.02, p<0.0001, n=3). In Aβ42O-treated neurons, 
although the extent of overlap between Syp and pSnpISer9 was reduced compared to synchronised 
neurons (M=0.36±0.15, p= 0.048, n=5), it was significantly higher compared to control neurons 
(p<0.0001). ***: p<0.0001, *: p<0.05. Scale bar, 10μm. 
Figure 3 
Representative images of double immunolabeling for Syp (green) and SnpI (red), in control (A-C) and 
VPA (10mM) treated primary hippocampal neurons (D-F) that were either non-synchronised (A, D), 
synchronised (B, E) or assayed 15min post synchronisation (C, F). High magnification of the boxed area 
is presented at the bottom of each picture. The extent of overlap between SnpI and Syp represented 
by the Mander’s coefficient (G) was similar between the two proteins in control and VPA treated non-
synchronised neurons (M=0.74±0.07 and 0.69±0.04, n=3). In synchronised neurons an increase was 
evident in VPA treated neurons compared to control (M=0.35±0.06 and 0.48±0.06, respectively, 
p=0.03, n=3). In contrast, no difference was observed between control and VPA treated neurons 
15min post synchronisation (M=0.64±0.05, 0.60±0.06). *: p<0.05. Scale bar, 10μm. 
Figure 4 
Representative images of double immunolabeling for Syp (green) and pSnpISer9 (red), in control (A-C) 
and VPA (10mM) treated primary hippocampal neurons (D-F) that were either non-synchronised (A, 
D), synchronised (B, E) or assayed 15min post synchronisation (C, F). High magnification of the boxed 
area is presented at the bottom of each picture. The extent of overlap between pSnpISer9 and Syp 
represented by the Mander’s coefficient (G) in non-synchronised neurons, was slightly increased in 
VPA treated neurons (M=0.19±0.08 for control and 0.28±0.09 For VPA treated neurons, p=0.026, n=3), 
whereas it was similar in synchronised and in 15min post-synchronised control and VPA treated 
neurons (M=0.45±0.05, 0.05±0.02 for control and 0.39±0.06, 11±0.09 for VPA treated neurons 
respectively, n=3). *: p<0.05. Scale bar, 10μm. 
Figure 5 
Representative images of double immunolabeling for Syp (green) and pSnpISer9 (red), in control (A), 
Aβ42O (300nM) treated (B) and Aβ42O/VPA (300nM and 10mM respectively) treated neurons (C) that 
were assayed 15min post synchronisation. High magnification of the boxed area is presented at the 
bottom of each picture. The extent of overlap between Syp and pSnpISer9 represented by the Mander’s 
coefficient (D) showed that the increase of pSnpISer9 at synaptic contacts induced by Aβ42O (0.36±0.15) 
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is reduced in the presence of VPA to similar levels as control neurons (0.09±0.02, and 0.06±0.02 
respectively, n=3). ***: p<0.0001. Scale bar, 10μm. 
Figure 6 
Western blotting of protein extracts from mature primary hippocampal neurons for SnpI (A) and 
SnpIpSer9 (C). The intensity ratios of SnpI/Act (B) and pSnpISer9/SnpI (D) were calculated for 
synchronised neurons (black bars) as well as for neurons 15min after depolarisation (white bars). All 
ratios were normalised to the SnpI/Act and pSnpISer9/SnpI ratios of synchronised control neurons. No 
significant differences in the levels of SnpI were observed (p values >0.1, n=4). Quantification of the 
signal intensity of pSnpISer9 over SnpI in synchronised neurons showed similar pSnpISer9 levels in all 
conditions (D), whereas in recovered neurons, a substantial decrease of pSnpISer9 levels was detected 
in control and VPA treated neurons (48.7%±11.9 in control, 42.5%±11.38 at 1mMVPA and 
47.8%±12.57 at 10mM VPA, p<0.05 n=4) compared to synchronised neurons. However, in Aβ42O 
treated neurons, pSnpISer9 levels remained elevated (74.07%±4.12, p=0.015 compared to control). 
After co-treatment with VPA, pSnpISer9 levels were restored to control levels in a concentration 
dependent manner (40.13±14.15 with 10mM VPA, p=0.005 and 55.82±13.48, p=0.045 with 1mMVPA, 
n=4).  **:p≤0.05, ***p<0.005. 
Figure 7 
Western blotting of protein extracts from mature primary hippocampal neurons for Tyr307-pPP2AC α/β 
and Actin (A). The intensity ratios of Tyr307-pPP2AC α/β /Act (B) were calculated and normalised to the 
Tyr307-pPP2AC α/β /Act ratio of synchronised control neurons. No significant differences in the levels 
of Tyr307-pPP2AC α/β were observed (p values >0.1, n=4).  
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Highlights 
 Activity dependent availability of synaptic vesicles is enhanced by Aβ42 oligomers  
 Aβ42 oligomers reduce the recovery of SnpI after neuronal activity 
 VPA reverses the effects of Aβ42 oligomers on SnpI 
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